Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Heidi D. Klepin, MD MS, Avrita Campinha-Bacote, Wan-Jen Hong, Patrick Phuong, Jue Wang, Mehrdad Mobasher, MD MPH, Peter Trask

Blood (2018) 132 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2018-99-116038

Published: 2018

Journal Articles

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Jennifer A. Woyach, MD, Ian W. Flinn, MD PhD, Deborah M. Stephens, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Sean D. Reiff, Ron E. Savage, Sudharshan Eathiraj, Lyndsey A. Szuszkiewicz, Kate Tith, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2018-99-116338

Published: 2018

Journal Articles

Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study

Ivy Altomare, MD, Aaron T. Gerds, MDMS, David Lessen, MD, Philomena Colucci, DO, MS, Shreekant Parasuraman, BPharm, PhD, Dilan Chamikara Paranagama, PhD, Ruben A. Mesa, MD FACP

Blood (2018) 132 (Supplement 1): 2259.

https://doi.org/10.1182/blood-2018-99-112937

Published: 2018

Journal Articles

The mouse that lost its appetite for human

William G. Kerr

Blood (2013) 122 (25): 4003–4004.

https://doi.org/10.1182/blood-2013-09-527614

Published: 2013

Journal Articles

Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

Jorge E. Cortes, Eric J Feldman, MD, Karen Yee, MD, David A. Rizzieri, MD, Anjali S. Advani, MD, Anthony Charman, PhD, Martin J. Toal, FFPM, Hagop M. Kantarjian

Blood (2011) 118 (21): 767.

https://doi.org/10.1182/blood.V118.21.767.767

Published: 2011

Journal Articles

Targeting EVI1-Overexpressing AML with Darinaparsin

Koren K Mann, PhD, Nathalie Johnson, MD, Torsten Holm Nielsen, MD, Nicolas Garnier, MSc, Stanley Kwan, Eftihia Cocolakis, PhD, Josee Hebert, MD, Robert Morgan, MSc, Wilson H. Miller, Jr., MD, PhD

Blood (2011) 118 (21): 4269.

https://doi.org/10.1182/blood.V118.21.4269.4269

Published: 2011

Journal Articles

Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL).

Barbara F. Eichhorst, MD, Kirsten Fischer, Anna- Maria Fink, MD, Guenter Fingerle-Rowson, MD, PhD, Anne Westermann, Clemens-Martin Wendtner, MD, Raymonde Busch, Michael Hallek, MD

Blood (2009) 114 (22): 3438.

https://doi.org/10.1182/blood.V114.22.3438.3438

Published: 2009

Journal Articles

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Wendy Stock, MD, Karen WL Yee, MD, Eunice S. Wang, MD, Sari Enschede, MD, Joyce Steinberg, MD, Rod Humerickhouse, MD, PhD, Qin Qin, PhD, Jiang Qian, PhD, Yi-Lin Chiu, PhD, Neeraj Gupta, PhD, Rajendra Pradhan, PhD

Blood (2008) 112 (11): 4008.

https://doi.org/10.1182/blood.V112.11.4008.4008

Published: 2008

Journal Articles

Baseline Characteristics Associated with Quality of Life in CLL Patients Requiring Therapy.

Monica Else, MSc, Alastair G. Smith, MD, Sue M. Richards, DPhil, Kim Cocks, MSc, Shirley Crofts, MSc, Daniel Catovsky, MD

Blood (2007) 110 (11): 2062.

https://doi.org/10.1182/blood.V110.11.2062.2062

Published: 2007

Journal Articles

Dectin-1: unique appetite for yeast

Cees van Kooten

Blood (2004) 104 (13): 3846.

https://doi.org/10.1182/blood-2004-09-3641

Published: 2004

NARROW

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study

The mouse that lost its appetite for human

Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

Targeting EVI1-Overexpressing AML with Darinaparsin

Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL).

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Baseline Characteristics Associated with Quality of Life in CLL Patients Requiring Therapy.

Dectin-1: unique appetite for yeast

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only